Concepts and clinical use of ultra-long basal insulin

Diabetes mellitus (DM) is a public health issue, affecting around 382 million people worldwide. In order to achieve glycemic goals, insulin therapy is the frontline therapy for type 1 DM patients; for patients with type 2 DM, use of insulin therapy is an option as initial or add-on therapy for those...

Full description

Saved in:
Bibliographic Details
Published in:Diabetology and metabolic syndrome 2016-01, Vol.8 (2), p.2-2, Article 2
Main Authors: Eliaschewitz, Freddy Goldberg, Barreto, Tânia
Format: Article
Language:English
Subjects:
Diabetes therapy
Health aspects
Insulin
Review
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Diabetes mellitus (DM) is a public health issue, affecting around 382 million people worldwide. In order to achieve glycemic goals, insulin therapy is the frontline therapy for type 1 DM patients; for patients with type 2 DM, use of insulin therapy is an option as initial or add-on therapy for those not achieving glycemic control. Despite insulin therapy developments seen in the last decades, several barriers remain for insulin initiation and optimal maintenance in clinical practice. Fear of hypoglycemia, weight gain, pain associated with blood testing and injection-related pain are the most cited reasons for not starting insulin therapy. However, new generation of basal insulin formulations, with longer length of action, have shown the capability of providing adequate glycemic control with lower risk of hypoglycemia.
ISSN:1758-5996
1758-5996
DOI:10.1186/s13098-015-0117-1